Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Moritz Fürstenau"'
Autor:
Anna-Maria Fink, Kirsten Fischer, Sandra Robrecht, Paula Cramer, Barbara Eichhorst, Petra Langerbeins, Anja Engelke, Stephan Stilgenbauer, Othman Al-Sawaf, Moritz Fürstenau, Michael Hallek, Jasmin Bahlo, Sebastian Boettcher, Von Tresckow Julia, Clemens M. Wendtner, Karl Anton Kreuzer, Matthias Ritgen
Publikováno v:
Journal of Clinical Oncology. 36:7513-7513
7513Background: The German CLL study group (GCLLSG) performed three similar phase-II-trials combining a CD20-antibody, ofatumumab (O) or obinutuzumab (G, for GA-101), with ibrutinib (I) or venetocl...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ad4ef585009113b7fc49f63673c7d5b2
https://doi.org/10.1200/jco.2018.36.15_suppl.7513
https://doi.org/10.1200/jco.2018.36.15_suppl.7513
Autor:
Barbara Eichhorst, Michael Gregor, Christian H. Geisler, Arnon P. Kater, Patrick Thornton, Niemann Carsten, Marinus H. J. van Oers, Tamar Tadmor, Eric Eldering, Matthias Ritgen, Stephan Stilgenbauer, Karl Anton Kreuzer, Michael Hallek, Kirsten Fischer, Jasmin Bahlo, Von Tresckow Julia, Moritz Fürstenau, Anna-Maria Fink
Publikováno v:
Journal of Clinical Oncology. 36:TPS7582-TPS7582
TPS7582Background: Chemoimmunotherapy (CIT) is still standard of care in first line treatment of fit CLL patients (pts) without del(17p) or TP53 mutation. However, CIT is often associated with side...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::87cf2da9a296e481d203bd3695999740
https://doi.org/10.1200/jco.2018.36.15_suppl.tps7582
https://doi.org/10.1200/jco.2018.36.15_suppl.tps7582